WANBURY
Back to Income Statement
|
WANBURY Last 5 Year Revenue History
[Consolidated]
| Mar2025 | Mar2024 | Mar2023 | Mar2022 | Mar2021 | |
|---|---|---|---|---|---|
| Net Sales | ₹600 Cr | ₹578 Cr | ₹500 Cr | ₹511 Cr | ₹393 Cr |
What is the latest Revenue of WANBURY ?
| Year | Revenue |
|---|---|
| Mar2025 | ₹600 Cr |
| Mar2024 | ₹578 Cr |
| Mar2023 | ₹500 Cr |
| Mar2022 | ₹511 Cr |
| Mar2021 | ₹393 Cr |
How is Revenue of WANBURY Trending?
| Years | Revenue | % Change | |
|---|---|---|---|
| Mar2025 | ₹600 Cr | 3.77 | |
| Mar2024 | ₹578 Cr | 15.63 | |
| Mar2023 | ₹500 Cr | -2.26 | |
| Mar2022 | ₹511 Cr | 30.23 | |
| Mar2021 | ₹393 Cr | - | |
Compare Revenue of peers of WANBURY
| Peers & Returns | Market Capitalization | 1 Week | 1 Month | 1 Year | ||
| WANBURY | ₹862.8 Cr | -3.3% | -10% | -11.8% | Stock Analytics | |
| SUN PHARMACEUTICAL INDUSTRIES | ₹455,634.0 Cr | -2.9% | -2.3% | 21.8% | Stock Analytics | |
| DIVIS LABORATORIES | ₹241,576.0 Cr | -1.6% | 9.8% | 51.8% | Stock Analytics | |
| TORRENT PHARMACEUTICALS | ₹184,478.0 Cr | -2.6% | -2.3% | 37.5% | Stock Analytics | |
| CIPLA | ₹111,888.0 Cr | -2.2% | -6.1% | -12.5% | Stock Analytics | |
| DR REDDYS LABORATORIES | ₹96,322.1 Cr | -0.9% | -1.8% | -9.8% | Stock Analytics | |
WANBURY Share Price vs Sensex
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
| WANBURY | -3.3% |
-10% |
-11.8% |
| SENSEX | -1% |
-2.6% |
-4.1% |
You may also like the below Video Courses